

# *Bioprosthetic Mitral Valve Thrombosis: 10 Years Single Center Experience*



**Bloch Lev**<sup>1</sup>, Ilan Bushari Limor<sup>1</sup>, Jabaren Mohamed <sup>1</sup>, Or Zafrir<sup>1</sup>,  
Orlov Boris<sup>2</sup>, Barak Yaron<sup>2</sup>, Aravot Dan<sup>2</sup> , Turgeman Yoav<sup>1</sup>

<sup>1</sup>Heart Institute , HaEmek Medical Center , Afula

<sup>2</sup>Heart Surgery Lady Davis Carmel Hospital , Haifa

***Conflict of Interest: None***


# *Background:*

- Mitral valves bioprosthesis (MVB ) are advantageous over mechanical devices as their incidence of thrombosis are significantly lower.
- However , the real prevalence of MVB thrombosis is unknown
- *Aim:* To determine the prevalence and predictors for MVB thrombosis

# *Material & Methods:*

- 10 years: 156 pts: MVR
- 35/156 (22.4%): Bioprosthetic MVR
- Mean age:  $68.7 \pm 9.5$

- *Valve Type :*



- *Etiology:* Ischemic 49% (17)  
Rheumatic 31% (11)  
Degenerative 17%(6)  
Endocarditis 3% (1)
- 35/156 (40%): Persistent AF – Rx - Coumadin



# *Results:*

- 3/35 (8.5%)- MVB Thrombi
- Mean period from surgery to index event:  $40 \pm 18$  months
- Sinus rhythm
- Ischemic etiology
- Echocardiography: LVEF  $< 35\%$  ( *$p < 0.05$* )
- 2/3- Redo (s/p CABG)
- 1/3- Coumadin for life



## *Conclusions:*

- **MVB thrombosis is a relatively frequent cause of valve dysfunction.**
- **The predictor of this phenomenon was significantly reduced LVEF in pts with ischemic etiology.**
- **In this group the need for early and long term anticoagulation should be considered.**